Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B

Journal of Medical Virology

Volumn 59, Issue 3, 1999, Pages 270-276

  Ogata, Norio ^a,b   Fujii, Kyuichi ^a   Takigawa, Shingo ^a   Nomoto, Minoru ^a   Ichida, Takafumi ^a   Asakura, Hitoshi ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

HBV breakthrough; HBV DNA; HIV; Reverse transcriptase; YMDD motif

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CATALYSIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; DNA STRAND BREAKAGE; DRUG EFFECT; DRUG EFFICACY; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; POLYMERASE CHAIN REACTION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADULT; ANTIVIRAL AGENTS; BASE SEQUENCE; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; GENOME, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; JAPAN; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; RNA-DIRECTED DNA POLYMERASE; SEQUENCE DELETION;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0032880610     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199911)59:3<270::AID-JMV2>3.0.CO;2-1     Document Type: Article

References (37)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters K-A, Tyrrell DLJ, Brown N for The Lamivudine Clinical Investigation Group, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Bain VG, Kneteman NM, Na MM, Gutfreund K, Shapiro JA, Fischer K, Tipples G, Lee H, Jewell LD, Tyrrell DL. 1996. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62:1456-1462.
3. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349: 20-22.
4. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. 1997. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 63:393-396.
5. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P. 1996. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 125:705-712.
6. Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Esteban R, Guardia J. 1998. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J Hepatol 28: 510-513.
7. Chang C-N, Doong S-L, Zhou JH, Beach JW, Jeong LS, Chu CK, Tsai C-H, Cheng Y-C. 1992a. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′ , 3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 267: 13938-13942.
8. Chang C-N, Skalski V, Zhou JH, Cheng Y-C. 1992b. Biochemical pharmacology of (+)- and (-)-2′ , 3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 267:22414-22420.
9. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology 27:1711-1716.
10. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
11. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 88:8495-8499.
12. Fu L, Cheng Y-C. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 55:1567-1572.
13. Girones R, Miller RH. 1989. Mutation rate of the hepadnavirus genome. Virology 170:595-597.
14. Gojobori T, Li W-H, Graur D. 1982. Patterns of nucleotide substitution in pseudogenes and functional genes. J Mol Evol 18:360-369.
15. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. 1996. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215.
16. Honkoop P, de Man RA, Zondervan PE, Schalm SW. 1997. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 17:103-106.
17. Keulen W, Boucher C, Berkhout B. 1996. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Res 31:45-47.
18. Ladner SK, Miller TJ, King RW. 1998. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrobial Agents Chemother 42:2128-2131.
19. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL, Gray DF for The Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
20. Lau DT-Y, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. 1997. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113: 1660-1667.
21. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
22. Lok ASF, Chung H-T, Liu VWS, Ma OCK. 1993. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105:1833-1838.
23. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NGB, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. 1998. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585-589.
24. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
25. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. 1998. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 65:1615-1621.
26. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, de Man RA, Thomas HC. 1997. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113:1258-1263.
27. Niesters HGM, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus ADME. 1998. Identification of more than one mutations in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 177:1382-1385.
28. Norder H, Hammas B, Lee S-D, Bile K, Courouce A-M, Mushahwar IK, Magnius LO. 1993. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol 74:1341-1348.
29. Ogata N, Miller RH, Ishak KG, Purcell RH. 1993. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 194:263-276.
30. Ogata N, Zanetti AR, Yu M, Miller RH, Purcell RH. 1997. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J Infect Dis 175:511-523.
31. Radziwill G, Tucker W, Schaller H. 1990. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 64:613-620.
32. Schalm SW, de Man RA, Heijtink RA, Niesters HGM. 1995. New nucleoside analogues for chronic hepatitis B. J Hepatol 22(Suppl 1):52-56.
33. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhillips P, Brown N, The International Lamivudine Investigator Group. 1998. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 28:388A.
34. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J, Boucher, CAB. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 171:1411-1419.
35. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vitro. Hepatology 24:714-717.
36. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heath-cote J. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 119:312-323.
37. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28: 1669-1673.